Clinical Trial Update: Avapritinib in CBF-AML With KIT Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Avapritinib in Core Binding Factor Acute Myeloid Leukemia with KIT mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Core-binding Factor Acute Myeloid Leukemia
• Kit Mutation-related Tumors

Drugs mentioned

• Avapritinib (avapritinib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors | Phase 2 | Status: UNKNOWN